Leoncon

Letrozole, the active ingredient in Leoncon, is an aromatase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women, helping to lower estrogen levels that can fuel tumor growth.

GNH USA supplies Leoncon as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to oncology centres, hospitals and pharmacies worldwide, including export to EU and other regulated markets, with traceable batch records and temperature‑controlled logistics where required.

Letrozole is an aromatase inhibitor used in the hormonal management of breast cancer. - Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen production to slow tumor progression. - Adjuvant therapy for early‑stage disease: decreases risk of cancer recurrence after surgery. - Metastatic breast cancer: helps control disease spread by limiting estrogen‑driven tumor growth.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching or stiffness in joints and muscles. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain in the head. - Increased sweating: excessive perspiration.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated liver enzymes. - Deep vein thrombosis or pulmonary embolism: blood clots in veins or lungs. - Bone fractures: increased risk due to reduced estrogen. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Elevated cholesterol levels: may worsen cardiovascular risk. - Severe hypertension: markedly high blood pressure.

Before initiating Letrozole therapy, clinicians should consider several safety measures. - Liver function monitoring: assess baseline enzymes and repeat periodically. - Bone health assessment: evaluate bone mineral density and consider supplementation. - Cardiovascular risk evaluation: review history of thrombosis or hypertension. - Pregnancy avoidance: Letrozole is contraindicated in pregnancy (Category X). - Osteoporosis caution: avoid in patients with severe bone loss unless benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Letrozole can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Tamoxifen: concurrent use may antagonize Letrozole’s anti‑estrogen effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can markedly lower Letrozole plasma levels. - Anticoagulants (e.g., warfarin): may increase bleeding risk.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine): may exacerbate hot flashes. - Statins: potential for increased myopathy risk. - Hormone replacement therapy: may counteract Letrozole’s estrogen suppression.